There is no approved retatrutide diet plan.
Retatrutide is an investigational triple agonist that has completed several phase 3 trials, but as of 20 July 2026 it has not been approved by the TGA or any other regulator. It is not a medicine people can lawfully buy from peptide websites, and no evidence-based public retatrutide meal plan has been established.
Do not take a product claiming to be retatrutide outside an authorised clinical trial.
Eli Lilly states that retatrutide has not been approved by any regulatory agency and warns that illicit products may contain unknown ingredients, contaminants, too much or too little active ingredient, or the wrong ingredient. The TGA also identifies retatrutide as an unapproved therapeutic good that cannot be advertised to the public.
A triple agonist, not “GLP-3”.
Retatrutide is being studied for effects at three receptors: GIP, GLP-1 and glucagon. “GLP-3” is an informal and scientifically inaccurate nickname; it is not a drug class or receptor.
The correct spelling is retatrutide. Search variations such as “retratutide” usually intend the same investigational compound. A search result does not establish that a product is genuine, approved or safe.
Trials included diet and activity.
Phase 3 programs studied retatrutide under controlled protocols, commonly alongside healthy diet and physical activity. That does not create a public treatment or meal plan.
No approved nutrition protocol.
There is no regulator-approved retatrutide Consumer Medicine Information, dose schedule or standard food list for public use.
Online “research” products.
Products sold online as retatrutide sit outside the safeguards of an authorised clinical trial and may be counterfeit or contaminated.
A “retatrutide meal plan” page can imply a treatment exists when it does not.
Some pages publish precise calorie plans, dosing-adjacent advice or claims about preventing side effects. Those claims should not be treated as established clinical guidance. Trial results answer research questions in selected participants; they do not validate a commercial diet plan for an unapproved medicine.
People seeking general information about eating with an approved GLP-1 or dual GIP/GLP-1 medicine should use the current Australian Product Information for that medicine and ask their own clinician or Accredited Practising Dietitian. Our general GLP-1 food guide discusses nutrition concepts without claiming they apply to investigational retatrutide.
Important: This is a regulatory and food-information explainer, not medical advice or promotion. Preptide does not supply, recommend or facilitate access to retatrutide or any prescription or investigational medicine. Regulatory status can change; check the TGA and the sponsor's official information. See our editorial policy.